BeiGene Ltd

Company Profile

BeiGene Ltd had its IPO on 2016-02-03 under the ticker symbol BGNE.

The company operates in the Healthcare sector and Biotechnology industry. BeiGene Ltd has a staff strength of 9,400 employees.

Stock update

Shares of BeiGene Ltd opened at $210.5 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $205.4 - $211.94, and closed at $206.72.

This is a -1.2% slip from the previous day's closing price.

A total volume of 136,236 shares were traded at the close of the day’s session.

In the last one week, shares of BeiGene Ltd have slipped by -1.05%.

BeiGene Ltd's Key Ratios

BeiGene Ltd has a market cap of $23.76 billion, indicating a price to book ratio of 4.6683 and a price to sales ratio of 16.8003.

In the last 12-months BeiGene Ltd’s revenue was $1.56 billion with a gross profit of $-511062000 and an EBITDA of $-1648758016. The EBITDA ratio measures BeiGene Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, BeiGene Ltd’s operating margin was -110.36% while its return on assets stood at -15.37% with a return of equity of -38.18%.

In Q1, BeiGene Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 46%.

BeiGene Ltd’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-18.39 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BeiGene Ltd’s profitability.

BeiGene Ltd stock is trading at a EV to sales ratio of 14.0405 and a EV to EBITDA ratio of -9.5817. Its price to sales ratio in the trailing 12-months stood at 16.8003.

BeiGene Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$5.96 billion

Total Liabilities

$1.25 billion

Operating Cash Flow

$0

Capital Expenditure

$125.59 million

Dividend Payout Ratio

0%

BeiGene Ltd ended 2024 with $5.96 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $5.96 billion while shareholder equity stood at $4.16 billion.

BeiGene Ltd ended 2024 with $0 in deferred long-term liabilities, $1.25 billion in other current liabilities, 136000.00 in common stock, $-7428773000.00 in retained earnings and $109000.00 in goodwill. Its cash balance stood at $3.54 billion and cash and short-term investments were $3.83 billion. The company’s total short-term debt was $306,353,000 while long-term debt stood at $206.30 million.

BeiGene Ltd’s total current assets stands at $4.70 billion while long-term investments were $97.95 million and short-term investments were $294.06 million. Its net receivables were $332.16 million compared to accounts payable of $241.36 million and inventory worth $297.00 million.

In 2024, BeiGene Ltd's operating cash flow was $0 while its capital expenditure stood at $125.59 million.

Comparatively, BeiGene Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$206.72

52-Week High

$280.62

52-Week Low

$124.46

Analyst Target Price

$316.74

BeiGene Ltd stock is currently trading at $206.72 per share. It touched a 52-week high of $280.62 and a 52-week low of $280.62. Analysts tracking the stock have a 12-month average target price of $316.74.

Its 50-day moving average was $198.91 and 200-day moving average was $221.84 The short ratio stood at 10.53 indicating a short percent outstanding of 0%.

Around 1984.2% of the company’s stock are held by insiders while 5248.5% are held by institutions.